Explore the words cloud of the Gri3D project. It provides you a very rough idea of what is the project "Gri3D" about.
The following table provides information about the project.
SUN BIOSCIENCE SA
|Coordinator Country||Switzerland [CH]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
|Duration (year-month-day)||from 2018-03-01 to 2018-08-31|
Take a look of project's partnership.
The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.
To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.
The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume. In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.
According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRI3D" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GRI3D" are provided by the European Opendata Portal: CORDIS opendata.
Super Productive Line Printing InkjetRead More
A 3D printed, affordable myoelectrical prosthetic hand of personalizeable size for optimal comfort and functionalityRead More
Safe, Transparent, Active and Reliable mineral sunscreen technologyRead More